Search research articles
Contact Us
Filters
Showing results (301-310 of 493) with videos related to
Page
of 50
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines
K A Margolin, A A Rayner, M J Hawkins, et al.
Blood
|
November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
J P Leonard, M L Sherman, G L Fisher, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
Michael B Atkins, Paolo A Ascierto, David Feltquate, et al.
JNCI Cancer Spectrum
|
July 31, 2018
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
Monica Girotra, Aaron Hansen, Azeez Farooki, et al.
Journal of Clinical Immunology
|
November 1, 1988
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients
J W Mier, G Vachino, J W van der Meer, et al.
The Oncologist
|
January 23, 2024
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial
Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K Callahan, Harriet Kluger, Michael A Postow, et al.
The Oncologist
|
May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Ryan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
British Journal of Cancer
|
June 16, 2011
Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
R S Bhatt, A J Zurita, A O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
M B Atkins, M T Lotze, J P Dutcher, et al.
Page
of 50
Search research articles
Search
Showing results (301-310 of 493) with videos related to
Sort By:
Page
of 50
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines
K A Margolin, A A Rayner, M J Hawkins, et al.
Blood
|
November 5, 1997
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
J P Leonard, M L Sherman, G L Fisher, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
Michael B Atkins, Paolo A Ascierto, David Feltquate, et al.
JNCI Cancer Spectrum
|
July 31, 2018
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
Monica Girotra, Aaron Hansen, Azeez Farooki, et al.
Journal of Clinical Immunology
|
November 1, 1988
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients
J W Mier, G Vachino, J W van der Meer, et al.
The Oncologist
|
January 23, 2024
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial
Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K Callahan, Harriet Kluger, Michael A Postow, et al.
The Oncologist
|
May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Ryan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
British Journal of Cancer
|
June 16, 2011
Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
R S Bhatt, A J Zurita, A O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
M B Atkins, M T Lotze, J P Dutcher, et al.
Page
of 50